Matthew Herder
Biographic Data
| ID | 2938248 |
|---|---|
| NAME | Matthew Herder |
| GIVEN NAMES | Matthew |
| FAMILY NAME | Herder |
| SIGNATURE | HERDER M |
| AFFILIATIONS | Dalhousie University |
| ORCID | 0000-0001-5319-6199 |
| VERIFIED | Yes |
| TOTAL WORKS | 8 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 7 |
| WORKS AS EDITOR | 1 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Competitive interdependence
This article investigates Canada's health product regulatory authority, Health Canada (HC), and other major national regulators' responses to COVID-19. Drawing on semi-structured interviews with HC officials and secondary data on the activities of other major regulators, including the European Medicines Agency, the United Kingdom's Medicines and Healthcare Products Regulatory Agency, and the United States Food and Drug Administration, we show tha…
Public sector innovation and the constraints of 'platform thinking
Scientists must recognize platform thinking to prevent it from unduly shaping the trajectory of biomedical research. Political and scientific leaders should invest in public-sector capacity so that promising technologies can be brought to the public without need for an industry partner in every instance
‘Our project, your problem?’ A case study of the WHO’s mRNA technology transfer programme in South Africa
In June 2021 the World Health Organization (WHO) and the Medicines Patent Pool (MPP) launched an mRNA technology transfer programme. With a South African consortium serving as the hub, the programme aimed to increase vaccine manufacturing capacity in low- and middle-income countries (LMICs) in view of the “vaccine apartheid” that was observed during COVID-19. Following Clarke’s “situational analysis,” the present study assessed whether the mRNA p…
Extending the US Food and Drug Administration’s Postmarket Authorities
Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…
Permissive regulation
Suboxone (buprenorphine-naloxone) is an opioid product approved in the US and Canada for the treatment of opioid use disorder. The drug is considered an important response to the opioid overdose epidemic with consistent calls for wider prescribing and deregulation. The history of Suboxone regulation in Canada has not been critically examined. Part of the rationale for doing so stems from the US regulatory experience, with documented irregularitie…
From sandbox to pandemic
Vulnerable
A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research
Governments and academic institutions have embraced the importance of commercializing research through the late twentieth century. In this study, we seek to understand scientists’ contemporary understanding of the role of academic science in this commercially oriented environment. We present findings based on 30 semi-structured interviews with biomedical researchers from different career stages at a medium-sized university in Canada about patenti…
No prominent works on this page.
A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research
Governments and academic institutions have embraced the importance of commercializing research through the late twentieth century. In this study, we seek to understand scientists’ contemporary understanding of the role of academic science in this commercially oriented environment. We present findings based on 30 semi-structured interviews with biomedical researchers from different career stages at a medium-sized university in Canada about patenti…
Vulnerable
From sandbox to pandemic
Permissive regulation
Suboxone (buprenorphine-naloxone) is an opioid product approved in the US and Canada for the treatment of opioid use disorder. The drug is considered an important response to the opioid overdose epidemic with consistent calls for wider prescribing and deregulation. The history of Suboxone regulation in Canada has not been critically examined. Part of the rationale for doing so stems from the US regulatory experience, with documented irregularitie…
Extending the US Food and Drug Administration’s Postmarket Authorities
Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…
‘Our project, your problem?’ A case study of the WHO’s mRNA technology transfer programme in South Africa
In June 2021 the World Health Organization (WHO) and the Medicines Patent Pool (MPP) launched an mRNA technology transfer programme. With a South African consortium serving as the hub, the programme aimed to increase vaccine manufacturing capacity in low- and middle-income countries (LMICs) in view of the “vaccine apartheid” that was observed during COVID-19. Following Clarke’s “situational analysis,” the present study assessed whether the mRNA p…
Public sector innovation and the constraints of 'platform thinking
Scientists must recognize platform thinking to prevent it from unduly shaping the trajectory of biomedical research. Political and scientific leaders should invest in public-sector capacity so that promising technologies can be brought to the public without need for an industry partner in every instance
Competitive interdependence
This article investigates Canada's health product regulatory authority, Health Canada (HC), and other major national regulators' responses to COVID-19. Drawing on semi-structured interviews with HC officials and secondary data on the activities of other major regulators, including the European Medicines Agency, the United Kingdom's Medicines and Healthcare Products Regulatory Agency, and the United States Food and Drug Administration, we show tha…
Medicine (5 works) · Business (4 works) · Economics (3 works) · Political science (3 works) · Public health (3 works) · Biomedical Ethics and Regulation (2 works) · Engineering (2 works) · Law (2 works) · Legislature (2 works) · Pharmaceutical Economics and Policy (2 works)